Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03860233 · ClinicalTrials.gov registry record · Phase 1

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

A Phase 1 study of Sleep Apnea, Obstructive and Sleep Apnea, sponsored by Vivek Jain.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT03860233: Recruiting Phase 1 study of Sleep Apnea, Obstructive and Sleep Apnea, sponsored by Vivek Jain.

NCT03860233 is a Phase 1 study of Sleep Apnea, Obstructive and Sleep Apnea that is actively recruiting participants, run by Vivek Jain. The registered enrollment target is 40 participants, below the 261-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03860233, a Phase 1 study of Sleep Apnea, Obstructive and Sleep Apnea, is actively recruiting participants, sponsored by Vivek Jain.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.

Primary Outcome

CPAP pressures will be monitored during study via electronic data retrieval system

Interventions

  • DRUG Placebo
  • DRUG Oxytocin

Study Locations (1)

District of Columbia

  • Medical Faculty Associates - Washington D.C.

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-03-04
Est. Completion 2026-03-01
Phase Phase 1
Vivek Jain

1 total trials

What NCT03860233 shows while recruiting

NCT03860233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 261-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Sleep Apnea, Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03860233 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT03860233 about?

NCT03860233 is a clinical study titled "Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine". This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study wi...

What is the current status of trial NCT03860233?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-03-04. Estimated completion is 2026-03-01.

What conditions does trial NCT03860233 study?

This clinical trial studies the following conditions: Sleep Apnea, Obstructive, Sleep Apnea.

What interventions are being tested in trial NCT03860233?

The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT03860233?

This trial is sponsored by Vivek Jain, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03860233 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Apnea, Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03860233's enrollment target sits among peer trials

40 29th of 45 higher than 15 of 45 other Sleep Apnea, Obstructive trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sleep Apnea, Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03860233, the US trial registry maintained by the National Library of Medicine. NCT03860233 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.